Continuous glucose monitoring in obese pregnant women with no hyperglycemia on glucose tolerance test

Imagem de Miniatura
Arquivos
art_RAHMI_Continuous_glucose_monitoring_in_obese_pregnant_women_with_2021.PDF (632.23 KB)
Citações na Scopus
4
Tipo de produção
article
Data de publicação
2021
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Autores
RAHMI, Rosa Maria
OLIVEIRA, Priscila de
SELISTRE, Luciano
PEZZELLA, Gabriela Neuvald
SANTOS, Pamela Antoniazzi dos
VERGANI, Daiane de Oliveira Pereira
MADI, Sonia Regina Cabral
MADI, Jose Mauro
Citação
PLOS ONE, v.16, n.6, article ID e0253047, 10p, 2021
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective The objective of the present study was to compare 24-hour glycemic levels between obese pregnant women with normal glucose tolerance and non-obese pregnant women. Methods In the present observational, longitudinal study, continuous glucose monitoring was performed in obese pregnant women with normal oral glucose tolerance test with 75 g of glucose between the 24(th) and the 28(th) gestational weeks. The control group (CG) consisted of pregnant women with normal weight who were selected by matching the maternal age and parity with the same characteristics of the obese group (OG). Glucose measurements were obtained during 72 hours. Results Both the groups were balanced in terms of baseline characteristics (age: 33.5 [28.7-36.0] vs. 32.0 [26.0-34.5] years, p = 0.5 and length of pregnancy: 25.0 [24.0-25.0] vs. 25.5 [24.0-28.0] weeks, p = 0.6 in the CG and in the OG, respectively). Pre-breakfast glycemic levels were 77.77 10.55 mg/dL in the CG and 82.02 +/- 11.06 mg/dL in the OG (p<0.01). Glycemic levels at 2 hours after breakfast were 87.31 <plus/minus> 13.10 mg/dL in the CG and 93.48 +/- 18.74 mg/dL in the OG (p<0.001). Daytime blood glucose levels were 87.6 <plus/minus> 15.4 vs. 93.1 +/- 18.3 mg/dL (p<0.001) and nighttime blood glucose levels were 79.3 <plus/minus> 15.8 vs. 84.7 +/- 16.3 mg/dL (p<0.001) in the CG and in the OG, respectively. The 24-hour, daytime, and nighttime values of the area under the curve were higher in the OG when compared with the CG (85.1 <plus/minus> 0.16 vs. 87.9 +/- 0.12, 65.6 +/- 0.14 vs. 67.5 +/- 0.10, 19.5 +/- 0.07 vs. 20.4 +/- 0.05, respectively; p<0.001). Conclusion The results of the present study showed that obesity in pregnancy was associated with higher glycemic levels even in the presence of normal findings on glucose tolerance test.
Palavras-chave
URI
https://observatorio.fm.usp.br/handle/OPI/41749
Referências
  1. Amer Diabet Assoc, 2020, DIABETES CARE, V43, pS183, DOI 10.2337/dc20-S014
  2. Amer Diabet Assoc, 2020, DIABETES CARE, V43, pS14, DOI 10.2337/dc20-S002
  3. [Anonymous], 2018, Obstet Gynecol, V131, pe49, DOI 10.1097/AOG.0000000000002501
  4. Barbour LA, 2018, CLIN THER, V40, P1638, DOI 10.1016/j.clinthera.2018.08.007
  5. Battelino T, 2019, DIABETES CARE, V42, P1593, DOI 10.2337/dci19-0028
  6. Behboudi-Gandevani S, 2019, DIABETOL METAB SYNDR, V11, DOI 10.1186/s13098-019-0406-1
  7. Calabuig-Navarro V, 2017, ENDOCRINOLOGY, V158, P2543, DOI 10.1210/en.2017-00152
  8. Catalano PM, 2012, DIABETES CARE, V35, P780, DOI 10.2337/dc11-1790
  9. Catalano PM, 1999, AM J OBSTET GYNECOL, V180, P903, DOI 10.1016/S0002-9378(99)70662-9
  10. Catalano PM, 2017, BMJ-BRIT MED J, V356, pJ1, DOI [DOI 10.1136/bmj.j1, 10.1136/bmj.j1]
  11. Chiefari E, 2017, J ENDOCRINOL INVEST, V40, P899, DOI 10.1007/s40618-016-0607-5
  12. Dutton H, 2018, MED CLIN N AM, V102, P87, DOI 10.1016/j.mcna.2017.08.008
  13. Feig DS, 2018, CAN J DIABETES, V42, pS255, DOI 10.1016/j.jcjd.2017.10.038
  14. Gaudet L, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/640291
  15. Gibson KS, 2012, OBSTET GYNECOL, V119, P560, DOI 10.1097/AOG.0b013e31824758e0
  16. Gomes D, 2018, PLOS MED, V15, DOI 10.1371/journal.pmed.1002681
  17. Harmon KA, 2011, DIABETES CARE, V34, P2198, DOI 10.2337/dc11-0723
  18. Kim SY, 2010, AM J PUBLIC HEALTH, V100, P1047, DOI 10.2105/AJPH.2009.172890
  19. McLachlan K, 2007, AUST NZ J OBSTET GYN, V47, P186, DOI 10.1111/j.1479-828X.2007.00716.x
  20. Metzger BE, 2008, NEW ENGL J MED, V358, P1991, DOI 10.1056/NEJMoa0707943
  21. Metzger BE, 2010, DIABETES CARE, V33, P676, DOI 10.2337/dc09-1848
  22. Pantham P, 2015, PLACENTA, V36, P709, DOI 10.1016/j.placenta.2015.04.006
  23. Plows JF, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113342
  24. Polsky S, 2017, DIABETES TECHNOL THE, V19, pS49, DOI 10.1089/dia.2017.0023
  25. Poston L, 2016, LANCET DIABETES ENDO, V4, P1025, DOI 10.1016/S2213-8587(16)30217-0
  26. Saltiel AR, 2017, J CLIN INVEST, V127, P1, DOI [10.1172/jci92035, 10.1172/JCI92035]
  27. Scott EM, 2020, DIABETES CARE, V43, P1178, DOI 10.2337/dc19-2527
  28. Tan E, 2014, CURR OPIN CLIN NUTR, V17, P343, DOI 10.1097/MCO.0000000000000061
  29. The National Institute for Health and Care Excellence, 2015, DIAB PREGN MAN PREC DIAB PREGN MAN PREC
  30. Wei Q, 2016, SCI REP-UK, V6, DOI 10.1038/srep19920
  31. World Health Organization, 2020, OB OV
  32. Yogev Y, 2004, AM J OBSTET GYNECOL, V191, P949, DOI 10.1016/j.ajog.2004.06.059

Coleções
Artigos e Materiais de Revistas Científicas - HC/InCor
Artigos e Materiais de Revistas Científicas - ODS/03